News
The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...
Sabic to close UK cracker, plastics recycler Novoloop raises funds, Kymera strikes molecular glue deal, and more ...
Moderna is preparing to test Health Secretary Robert F. Kennedy Jr.'s tougher vaccine policies with a combination flu-COVID ...
Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about ...
Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...
Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...
This summary encapsulates recent health updates including Carmat's insolvency filing, Bayer's glyphosate litigation in the U.S. Supreme Court, FDA's label revisions for ADHD stimulants, a U.S. House ...
Moderna shares rose on the increased effectiveness of its flu vaccine in late-stage trials, bring the biotech company closer ...
Moderna’s experimental mRNA-based flu vaccine demonstrated a stronger immune response than a currently available standard flu shot in a late-stage phase 3 trial, clearing a path for regulatory ...
The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.
RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older ...
Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results